U.S. Development Programs.

Lundbeck Inc.'s pipeline consists of late-stage investigational programs relating to Central Nervous System (CNS) diseases and disorders.

Compound (Target area of research)

Activity

Phase I

Phase II

Phase III

Registration application

Sertindole US
Schizophrenia

Dopamine/serotonin

Clobazam
Lennox-Gastaut syndrome

Benzodiazepine

2011

Lu AA21004
Depression + GAD

Multi-modal neurotr. enhancer

2012

I.V. Carbamazepine
Epilepsy

Intravenous carbamazepine

2012

Desmoteplase
Stroke

Plasminogen activator

2012+

Lu AA24530
Depression

Multiple targets

2012+

Lu 31-130
Psychosis

Monoaminergic

2012+

Lu AE58054
Psychosis

Selective 5-HT6 antagonist

2012+

Lu AA39959
Psychosis/bipolar

Ion Channel Modulator

2012+

Lu AA24493
Stroke/neuronal damage

Tissue protective cytokine

2012+

Lu 02-750
Parkinson's disease

Dopaminergic agent

2012+

Lu AE04621
Parkinson's disease

Dopaminergic agent

2012+

The information provided on this page is for general information only and is not intended to provide medical advice or guidance and should not be used for that purpose.  A drug is not considered safe or effective for its intended use unless approved by the FDA.
Close

Compound (Target area of research)

Sertindole US

Indication:

Schizophrenia

Activity:

Dopamine/serotonin

Phase:

filed

Close

Compound (Target area of research)

Clobazam

Indication:

Lennox-Gastaut syndrome

Activity:

Benzodiazepine

Phase:

III

Close

Compound (Target area of research)

Lu AA21004

Indication:

Depression + GAD

Activity:

Multi-modal neurotr. enhancer

Phase:

III

Close

Compound (Target area of research)

I.V. Carbamazepine

Indication:

Epilepsy

Activity:

Intravenous carbamazepine

Phase:

III

Close

Compound (Target area of research)

Desmoteplase

Indication:

Stroke

Activity:

Plasminogen activator

Phase:

III

Close

Compound (Target area of research)

Lu AA24530

Indication:

Depression

Activity:

Multiple targets

Phase:

II

Close

Compound (Target area of research)

Lu 31-130

Indication:

Psychosis

Activity:

Monoaminergic

Phase:

II

Close

Compound (Target area of research)

Lu AE58054

Indication:

Psychosis

Activity:

Selective 5-HT6 antagonist

Phase:

II

Close

Compound (Target area of research)

Lu AA39959

Indication:

Psychosis/bipolar

Activity:

Ion Channel Modulator

Phase:

II

Close

Compound (Target area of research)

Lu AA24493

Indication:

Stroke/neuronal damage

Activity:

Tissue protective cytokine

Phase:

II

Close

Compound (Target area of research)

Lu 02-750

Indication:

Parkinson's disease

Activity:

Dopaminergic agent

Phase:

I

Close

Compound (Target area of research)

Lu AE04621

Indication:

Parkinson's disease

Activity:

Dopaminergic agent

Phase:

I

This site contains medical information that is intended for residents of the United States only and is not meant to
substitute for the advice provided by a medical professional. Always consult a physician if you have health concerns.
Use and access of this site is subject to the terms and conditions as set out in our Privacy Policy and Terms of Use.
© Copyright 2010 Lundbeck Inc. All rights reserved.
Phone: 866-337-6996
Fax: 847.282.1001
contact@lundbeck.com